Cell Therapy MDR-101 Produces Functional Immune Tolerance in Kidney Transplant Recipients

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 15, 2025.

via HealthDay

TUESDAY, July 15, 2025 -- Kidney transplant recipients receiving the investigational cellular product MDR-101 achieved functional immune tolerance for more than two years, according to a study published in the July issue of the American Journal of Transplantation.

Dixon B. Kaufman, M.D., Ph.D., from the University of Wisconsin School of Medicine and Public Health in Madison, and colleagues conducted a phase 3 randomized trial to examine MDR-101 for producing immune tolerance versus standard of care in kidney transplant recipients. Adult recipients of kidneys from 2-haplotype human leukocyte antigen-matched living siblings were randomly allocated to treatment or control (20 and 10, respectively). Treatment recipients received a nonmyeloablative conditioning protocol with rabbit-antithymocyte globulin and 10 fractions of low-dose total lymphoid irradiation. On day 11, MDR-101 was infused. Steroids and mycophenolate were withdrawn by day 10 and day 39, respectively. Tacrolimus was continued until day 180, and if donor hematopoietic mixed chimerism was ≥5 percent, it was tapered to withdrawal one year posttransplant. Per institutional standard of care, controls received immunosuppression.

The researchers found that none of the 20 recipients of MDR-101 developed graft-versus-host disease. Approximately one year after transplant, 95 percent successfully discontinued all immunosuppression. Seventy-five percent reached the primary study end point of immunosuppression-free for more than two years. Four resumed immunosuppression: one each with recurrent immunoglobulin A nephropathy, recurrent immunoglobulin A nephropathy and rejection, rejection, and borderline biopsy changes.

"In the scheme of things, this research is right at the very top," coauthor Mark D. Stegall, from the Mayo Clinic in Rochester, Minnesota, said in a statement. "It's been a goal -- to be able to safely get transplant recipients off immunosuppression -- for longer than I've been doing this."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-16 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords